iOnctura appoints Paul Sekhri as Chair of its Board of Directors
Key Highlights
- ➤Paul Sekhri appointed iOnctura Board Chair, effective immediately
- ➤Roginolisib’s two randomized studies fully enrolled ahead of Phase III development
- ➤iOnctura prepares late-stage development of roginolisib in neglected cancers
- ➤Paul Sekhri brings more than 35 years of life sciences experience
Expert Statements
Catherine Pickering, CEO and co-founder of iOnctura
“Paul brings an exceptional combination of biotechnology leadership, strategic vision and capital markets expertise that will be invaluable as we enter our next phase of growth.”
Catherine Pickering, CEO and co-founder of iOnctura
“As roginolisib advances toward Phase III development, his experience building, financing and leading innovative life science companies will help position iOnctura for long-term success.”
Catherine Pickering, CEO and co-founder of iOnctura
“Our ability to attract a leader of Paul’s caliber reflects both the strength of our science and the opportunity ahead.”
Catherine Pickering, CEO and co-founder of iOnctura
“I look forward to working closely with him as we continue our mission of bringing new treatment options to patients with neglected and hard-to-treat cancers.”
Catherine Pickering, CEO and co-founder of iOnctura
“On behalf of the Board, I would also like to thank Dr. Mark Velleca for his contributions as Chair and wish him well for the future.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“PI3Kδ is a validated target, but first generation inhibitors could not be dosed safely for long enough to make a meaningful difference to patients.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“Roginolisib’s unique ability to lock PI3Kδ in its inactive state is the most convincing solution to that challenge I have seen.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“The survival signal in uveal melanoma, where patients have very few options, underscores its potential.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“With two randomized studies fully enrolled, the upcoming readouts will define roginolisib’s path into pivotal development.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“As Chair, my focus is to ensure iOnctura has the capital and partnerships to move quickly as opportunities emerge.”
Paul Sekhri, Chair of the Board of Directors of iOnctura
“I have sat on a lot of boards at this stage of a company’s life, and few have had a clearer set of near-term catalysts.”
* Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization * Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled * Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with immediate effect.
Paul’s career spans business development, corporate strategy, M&A and financing across large pharma, biotech and private equity. He has served on more than 40 public, private and non-profit boards, 18 of them as Chair.
Get started
Create a free account to read the full story.